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ABSTRACT 
Kinesin family member 14 (KIF14), a microtubule-based motor protein, plays an 
important role in chromosomal segregation, congression, and alignment. Considerable 
evidence indicates that KIF14 is involved in cytokinesis, although little is known about its 
role in oral squamous cell carcinomas (OSCCs). In the current study, we functionally and 
clinically investigated KIF14 expression in patients with OSCC. Quantitative reverse 
transcriptase-polymerase chain reaction and immunoblotting analyses were used to assess 
the KIF14 regulatory mechanism in OSCC. Immunohistochemistry (IHC) was performed 
to analyze the correlation between KIF14 expression and clinical behavior in 104 patients 
with OSCC. A KIF14 knockdown model of OSCC cells (shKIF14 cells) was used for 
functional experiments. KIF14 expression was up-regulated significantly (P < 0.05) in 
OSCCs compared with normal counterparts in vitro and in vivo. In addition, shKIF14 cells 
inhibited cellular proliferation compared with control cells by cell-cycle arrest at the 
G2/M phase through up-regulation of G2 arrest-related proteins (p-Cdc2 and cyclin B1). 
As expected, IHC data from primary OSCCs showed that KIF14-positive patients 
exhibited significantly (P < 0.05) more larger tumors compared with KIF14-negative 
patients. The current results suggest for the first time that KIF14 is an indicator of tumoral 
size in OSCCs and that KIF14 might be a potential therapeutic target for development of 
new treatments for OSCCs. 
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1. Introduction 
Kinesins are a family of the ATP-dependent motor proteins that travel unidirectionally 
along microtubule tracks to fulfill their many roles in intracellular transport or cell 
division [1-3]. Kinesins have so far been classified into 14 subfamilies (kinesin-1 family 
to kinesin-14 family) by phylogenetic analysis of the motor domain [1, 4] and are 
additionally composed of 45 kinesin superfamily proteins (KIFs) [1, 5]. KIFs reportedly 
transport organelles or participate in signal transduction, but mainly participate in cell 
mitosis, particularly in spindle formation, chromosomal and nuclear movement, and 
cytokinesis [5]. 
Previous studies also have indicated that KIFs play critical roles in several 
malignancies, including tumoral development and progression [1, 2, 4-10]. Among them, 
KIF14 protein is localized at the spindle midzone (the area formed between retreating 
chromosomes as they segregate toward the spindle poles in anaphase) and the midbody 
(the cytoplasmic bridge that connects two daughter cells at the end of cytokinesis in 
telophase) [11, 12], and is essential for cytokinesis and chromosome segregation. KIF14 
has genomic gain at 1q31.3–1q32.1 with overexpressed gene levels in multiple cancers, 
i.e., breast, retinoblastoma, liver, renal, lung, laryngeal, and ovarian cancers and synovial 
sarcoma [13-28]. However, the relationship between overexpression of KIF14 and clinical 
behavior of oral squamous cell carcinoma (OSCC) has not yet been clarified. 
In the current study, we report that KIF14 expression in OSCCs is functionally and 
clinically linked to tumoral size in vitro and in vivo and show that KIF14 is closely related 
to the cell cycle. Therefore, KIF14 might be a potential therapeutic target for OSCCs. 
 
 
  
 
2. Materials and methods 
2.1. Ethics statement 
The Ethical Committee of the Graduate School of Medicine, Chiba University 
approved the study protocol (approval number, 236); the study was performed in 
accordance with the tenets of the Declaration of Helsinki. All patients provided written 
informed consent before participating in this research. 
 
2.2. OSCC-derived cell lines and tissue specimens 
Human OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, KOSC-2, Ca9-22, Ho-1-N-1, 
Ho-1-u-1, and SAS) were obtained from the Human Science Research Resources Bank 
(Osaka, Japan) or the RIKEN BioResource Center (Ibaraki, Japan). Primary cultured 
human normal oral keratinocytes (HNOKs) were obtained from three healthy donors and 
served as normal controls [29, 30]. All cells were grown in Dulbecco’s modified Eagle 
medium (Sigma-Aldrich Co, St. Louis, MO, USA) supplemented with 10% fetal bovine 
serum (Sigma) and 50 units/ml penicillin and streptomycin (Sigma). Clinicopathologic 
staging was determined by the TNM classification of the International Union against 
Cancer [31].  
 
2.3. Preparation of cDNA and protein 
Total RNA and protein were isolated as described previously [28,29].  
 
2.4. mRNA expression analysis 
Real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
was conducted as described previously [28,29]. Primers and universal probes were 
  
 
designed using the Universal Probe Library Assay Design Center (Roche Diagnostics 
GmbH), which specifies the most suitable set. The primer sequences used for 
qRT-PCR were: KIF14, forward, 5′-CCTGTCTTTTTGCTTATGGTCAG-3′; reverse, 
5′-TCTTCACTAAATCCCATCATCG -3′; and universal probe #21, and the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward, 5’- 
AGCCACATCGCTCAGACAC-3’; reverse, 5’-GCCCAATACGACCAAATCC-3’; 
and universal probe #60.  
 
2.5. Immunoblotting analysis 
 Immunoblotting analysis was performed as described previously [28,29]. The 
antibodies were rabbit anti-KIF14 polyclonal antibody (Cat. No. A300-912A, Bethyl 
Laboratories, Montgomery, AL, USA), mouse anti-GAPDH monoclonal antibody (Cat. 
No. sc-32233, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit 
anti-phospho-CDC2 polyclonal antibody (Cat. No. sc-101654, Santa Cruz Biotechnology), 
and rabbit anti-cyclin B1 polyclonal antibody (Cat. No. 12231, Cell Signaling Technology, 
Danvers, MA, USA). 
 
2.6. IHC 
IHC using the primary antibody was performed as previously described [32, 33]. To 
quantify the KIF14 protein expression in those components, we used the previously 
described IHC scoring system [32, 33]. To determine the cutoff points of KIF14 IHC 
scores, we analyzed the IHC scores of 104 patients using the receiver operating 
characteristic (ROC) curve. Cases with a score following over 95.0 (Youden Index and 
ROC curve for tumoral tissue) were considered KIF14-positive. Two independent 
  
 
pathologists from Chiba University Hospital, neither of whom had knowledge of the 
patients’ clinical status, made these judgments. 
 
2.7. Transfection with shRNA plasmid 
 A total of 1×10
5 
cells from the Ho-1-N-1and SAS cell lines were transfected with 
10 ng/µl KIF14 shRNA (shKIF14) or 10 ng/µl control shRNA (shMock) vectors 
(Santa Cruz Biotechnology) using 1.25 µl Lipofectamine index LTX and 0.5 µl Plus 
Reagents (Invitrogen, Carlsbad, CA, USA). The stable shKIF14 and shMock cells 
were isolated using a culture medium containing 1 µg/ml puromycin (Santa Cruz 
Biotechnology). 
 
2.8. Cellular growth 
To evaluate the effect of KIF14 knockdown on cellular growth, we analyzed 
cellular growth in the shKIF14 and shMock cells. These cells were seeded in 6-cm 
plates at a density of 1×10
4
 viable cells. A cellular growth assay was performed as 
described previously [28,29]. 
 
2.9. Cell-cycle analysis 
To synchronize cells at the G0/G1 or G2/M transition, the cells were cultured in 
serum free media for 48 hours or treated with 200 ng/ml nocodazole (Sigma) for 12 
hours [34, 35]. Cell-cycle analysis was performed as described previously [28]. 
 
2.10. Statistical analysis 
In comparisons of KIF14 expression levels, statistical significance was evaluated 
  
 
using the Mann-Whitney U-test. Relationships between the KIF14-IHC scores and 
clinicopathological profiles were evaluated using the Mann-Whitney U-test. P < 0.05 
was considered significant. The data are expressed as the mean ± standard error of the 
mean (SEM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
3. Results 
3.1. Evaluation of KIF14 expression in OSCC-derived cell lines 
To investigate the expression status of KIF14, we performed qRT-PCR and 
immunoblotting analyses using eight OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, 
KOSC-2, Ca9-22, Ho-1-N-1, Ho-1-u-1, and SAS) and HNOKs. KIF14 mRNA was 
up-regulated significantly (P < 0.05) in all OSCC-derived cell lines compared with the 
HNOKs (Fig. 1A). Representative results of immunoblotting analysis are shown in Fig. 
1B. The KIF14 protein expression was up-regulated significantly (P < 0.05) in all 
OSCC-derived cell lines compared with the HNOKs.  
 
3.2. Evaluation of KIF14 expression in primary OSCCs 
Representative IHC results for KIF14 protein in primary OSCCs and adjacent 
normal oral tissue are shown in Fig. 2A and B, respectively. Strong KIF14 
immunoreactivity was detected in the nucleus of OSCC tissues, whereas the normal 
tissues showed almost negative immunostaining. We analyzed the KIF14 protein 
expression in primary OSCCs from 104 patients using the IHC scoring system [36, 37]. 
The KIF14 IHC scores in OSCCs and adjacent normal oral tissues ranged from 70 to 
230 (median, 150) and 10 to 135 (median, 65), respectively. The IHC scores in primary 
OSCCs were significantly (P < 0.05) higher than in normal oral tissues (Fig. 2C). To 
determine an optimal cutoff point of the identified IHC scores, we used the Youden 
Index and ROC curve analyses. In addition to the data from the Youden Index 
(sensitivity, 79.8%; specificity, 90.4%, P < 0.05), ROC curve analysis showed that 
the cutoff value was 95.0 (Fig. 2D, E). 
 
  
 
3.3. Establishment of KIF14 knockdown cells 
Since frequent up-regulation of KIF14 occurred in OSCC-derived cells (Fig. 1), the 
OSCC-derived cells (Ho-1-N-1 and SAS) were transfected with KIF14 shRNA and 
shMock as controls. To confirm the efficiency of shKIF14 transfection, we performed 
qRT-PCR and immunoblotting analyses (Fig. 3A, B). KIF14 mRNA expression in 
shKIF14 cells was significantly (P < 0.05) lower than in the shMock cells (Fig. 3A). 
The KIF14 protein level in the shKIF14 cells also decreased compared with the shMock 
cells (Fig. 3B). 
 
3.4. Cellular proliferation of KIF14 knockdown cells 
To evaluate the effect of KIF14 knockdown on cellular growth, we performed a 
cellular proliferation assay (Fig. 3C). We found a significant (P < 0.05) decrease in 
cellular growth in shKIF14 cells compared with shMock cells. Therefore, the assays 
showed that KIF14 knockdown decreased cellular growth. 
 
3.5. Cell-cycle analysis of KIF14 knockdown cells 
To investigate the mechanism by which KIF14 is related to cellular proliferation, we 
performed cell-cycle analysis of KIF14 knockdown cells using Ho-1-N-1 and SAS. The 
percentage of the shKIF14 cells in the G2/M phase was significantly (P < 0.05) higher 
than in the Mock cells (Fig. 4A). We also assessed the expression levels of the G2 
arrest-related proteins, p-Cdc2 and cyclin B1. As expected, these were up-regulated in 
shKIF14 cells (Fig. 4B). These results indicated that shKIF14 cells inhibited cellular 
proliferation by cell-cycle arrest at the G2/M phase. 
 
  
 
3.6. Correlation between KIF14 expression and clinical classifications in primary 
OSCCs 
The correlations between the clinicopathological characteristics of the patients with 
OSCC and the status of KIF14 protein expression using the IHC scoring system are 
shown in Table 1. Among the clinical parameters, significant (P = 0.019) differences in 
tumoral size in KIF14-positive patients with OSCC were seen compared with 
KIF14-negative patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
4. Discussion 
The current study provided the first evidence that KIF14 overexpression occurs in 
OSCCs and is positively correlated with tumoral size. In other cancers, KIF14 
expression was associated with lymph node metastasis, stage, and grade [38, 39]. 
Therefore, we assumed that KIF14 may have different functions in difference cancer 
types. In addition, our KIF14 knockdown experiments showed that KIF14 controlled 
cellular proliferation by arresting cell-cycle progression at the G2/M phase, suggesting 
that KIF14 plays a significant role in tumoral size in human OSCCs. 
Genomic amplifications, 1q31.3-1q32.1, are observed in several types of cancer, 
leading to overexpression of KIF14 mRNA and protein [13-24, 28]. In addition, 
overexpressed KIF14 mRNA and protein were reported as potential prognostic markers 
and therapeutic targets in retinoblastoma and breast, lung, and ovarian cancers [15, 16, 
24, 28, 40]. In contrast, low expression of KIF14 was associated with poor overall 
survival in patients with lung adenocarcinoma [38]. Therefore, KIF14 plays pivotal 
roles in development and progression of several types of cancers. 
Transient KIF14 knockdown cervical cancer cells showed significantly decreased 
proliferative and colony forming capabilities [39, 41]; however, the reasons for the 
cellular behaviors are unknown. Our previous study reported that KIF4A is closely 
related to the spindle assembly checkpoint (SAC) [36]; therefore, we speculated here 
that KIF14 is associated with cytokinesis and has a critical role in cell-cycle arrest [11, 
12]. Consistent with our hypothesis, our KIF14 knockdown models showed cell-cycle 
arrest at the G2/M phase by activation of G2 arrest-related proteins. Interestingly, KIF14 
did not participate in the SAC (data not shown), whereas KIF14 and KIF4A are similar 
kinesin superfamily proteins. 
  
 
Radiation therapy is a major adjuvant treatment for patients with OSCC. The cells in 
the G2/M phase are highly radiosensitive, whereas the cells in the G0 and G1/S phases 
have low radiosensitivity. Since KIF14 knockdown led to cell-cycle arrest at the G2/M 
phase, combination radiation therapy with KIF14 inhibition seems critical for patients 
with OSCC. 
In the current study, we found that KIF14 plays an important role in OSCC growth; 
therefore, KIF14 expression is likely to be a biomarker of proliferation and a potential 
therapeutic target for development of anticancer therapy for OSCC. 
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Legends 
Fig. 1. Evaluation of KIF14 expression in OSCC-derived cell lines. (A) Quantification of 
KIF14 mRNA expression in OSCC-derived cellular lines by qRT-PCR analysis. 
Significant up-regulation of KIF14 mRNA is seen in eight OSCC-derived cellular lines 
compared with the HNOKs (P < 0.05, Mann-Whitney U-test). Data are expressed as the 
means ± SEM of triplicate results. (B) Immunoblotting analysis of KIF14 protein in the 
OSCC-derived cell lines and HNOKs. KIF14 protein expression is up-regulated in the 
OSCC-derived cell lines compared with that in the HNOKs. Densitometric KIF14 protein 
data are normalized to GAPDH protein levels.  
 
Fig. 2. Evaluation of KIF14 expression in primary OSCCs. (A, B) Representative IHC 
results for KIF14 protein in primary OSCCs and normal oral tissue (Scale bars, 10 μm). 
Strong KIF14 immunoreactivity is detected in the nuclei of primary OSCCs; normal oral 
tissues show almost negative immunostaining. (C) The state of KIF14 protein expression 
in primary OSCCs (n=104) and the normal counterparts. The KIF14 IHC scores for 
normal oral tissues and OSCCs range from 10 to 135 (median, 65) and 70 to 230 (median, 
150), respectively. KIF14 protein expression levels in OSCCs are significantly (P < 0.05, 
Mann-Whitney’s U test) higher than in normal oral tissues. (D) Youden Index analysis 
shows that the optimal cutoff point is 95.0. (E) ROC curve analysis shows that the 
optimal cutoff point is 95.0. 
 
Fig. 3. Establishment of KIF14 knockdown cells and cellular proliferation of KIF14 
knockdown cells. (A) qRT-PCR shows that KIF14 mRNA expression in the shKIF14 cells 
(Ho-1-N-1-and SAS-derived transfectants; 2 clones each) is significantly (P < 0.05, 
  
 
Mann-Whitney U-test) lower than in the shMock cells. (B) Immunoblotting analysis 
shows that the KIF14 protein levels in shKIF14 cells (Ho-N-1- and SAS-derived 
transfectants; 2 clones each) also have decreased markedly compared with that in the 
shMock cells. (C) To determine the effect of shKIF14 on cellular proliferation, shKIF14 
and shMock cells were seeded in six-well plates at a density of 1×10
4 
viable cells/well. 
Both transfectants were counted on seven consecutive days. The cellular growth of 
shKIF14 cells (Ho-1-N-1- and SAS-derived transfectants; 2 clones each) are significantly 
(P < 0.05, Mann-Whitney U test) inhibited compared with the shMock cells after 72 
(Ho-1-N-1) and 96 (SAS) hours. The results are expressed as the means ± SEM of values 
from three assays.  
 
Fig. 4. Cell-cycle analysis of KIF14 knockdown cells. (A) Flow cytometric analysis was 
performed to investigate the cell cycle in shKIF14 and shMock cells. The percentage of 
the G2/M phase in shKIF14 cells (Ho-N-1- and SAS-derived transfectants; 2 clones each) 
has increased markedly compared with the shMock cells (P < 0.05, Mann-Whitney U-test). 
(B) shKIF14 cells show up-regulation of p-Cdc2 and cyclin B1 (Ho-N-1- and 
SAS-derived transfectants; 2 clones each) compared with shMock cells (P < 0.05, 
Mann-Whitney U test).  
 
 
 
 
 
 
  
 
Table 1. Correlation between KIF14 expression and clinical classification in OSCCs  
Clinical classification 
  Results of immunostaining 
No of patients (%) 
  
  
  Total KIF14  
negative 
KIF14 
positive 
P value 
Age at surgery (years) 
      <60 18 9 (50)    9 (50) 
0.382   ≧60, <70 24  8 (35)   16 (65) 
  ≧70 62 23 (37)   39 (63) 
Gender 
      Male 65 24 (37)   41 (63) 
0.438 
  Female 39 16 (41)   23 (59) 
T-primary tumor 
      T1 6  4 (67)    2 (33) 
0.019＊
   T2 54 25 (46)   29 (54) 
  T3 20  6 (30)   14 (70) 
  T4 24  5 (22)   19 (78) 
N-regional lymph node 
     negative 62 22 (35)   40 (65) 
0.121 
  positive 42 18 (44)   24 (56) 
Stage 
      I 5  3 (60)    2 (40) 
0.563 
  II 42 17 (37)   25 (63) 
  III 19  6 (32)   13 (68) 
  IV 38 14 (39)   24 (61) 
Vascular invasion 
    negative 85 36 (43) 49 (57) 
0.439 
positive 19  4 (21) 15 (79) 
Histopathologic type     
  Well 64 24 (38)   40 (62) 
0.512   Moderately 33 13 (40)   20 (60) 
  Poorly 7  3 (43)    4 (57) 
Tumoral site 
      Gingiva 30 15 (50)   15 (50) 
0.471 
  Tongue 58 20 (35)   38 (65) 
  Buccal mucosa 10  4 (40)    6 (60) 
  Oral floor 6  1 (17)    5 (83) 
＊P < 0.05 was considered significant. 
 
 
 
 
 
 
010
20
30A 
KIF14 
GAPDH 
B 
Figure 1 
* 
* * 
* 
* * 
* 
m
R
N
A
 R
e
la
ti
v
e
 
E
x
p
re
s
s
io
n
 
 
(K
IF
1
4
/G
A
P
D
H
) 
* 
0
300
600
900
%
 o
f 
c
o
n
tr
o
l 
K
IF
1
4
  
IH
C
 s
c
o
re
 
(%
 i
n
te
n
s
it
y
 o
f 
Im
m
u
n
o
re
a
c
ti
o
n
) 
A 
×100 
B 
×100 
Figure 2 
C 
Normal 
tissues 
0
50
100
150
200
250
OSCCs 
* 
s
e
n
s
it
iv
it
y 
Cutoff : 95.0 
AUC : 0.932 
D 
0 
0 1 
1 
0.5 
0.5 
0 
0 1 
1 
0.5 
0.5 
1- specificity 
1- specificity 
E 
1
-s
e
n
s
it
iv
it
y 
-s
p
e
c
if
ic
it
y 
 
Cutoff : 95.0 
shMock
shKIF14-1
shKIF14-2
* 
* 
* 
* 
* * 
A 
KIF14 
GAPDH 
B 
Figure 3 
SAS Ho-1-N-1 
* 
* 
SAS Ho-1-N-1 
m
R
N
A
 R
el
a
ti
ve
 E
xp
re
ss
io
n
 
 (
K
IF
1
4
/G
A
P
D
H
) 
1.0 
0.5 
0 
%
 o
f 
c
o
n
tr
o
l 
* * 
* 
* * 
Time (hours) 
Time (hours) 
SAS 
shMock 
shKIF14-1 
shKIF14-2 
C
e
ll
 n
u
m
b
e
r 
(x
1
0
4
) C 
C
e
ll
 n
u
m
b
e
r 
(x
1
0
4
) 
Ho-1-N-1 
100 
50 
0 
80 
60 
40 
20 
0 
80 
60 
40 
20 
0 
0 24 48 72 96 120 144 168 
0 24 72 120 168 48 96 144 
shMock 
shKIF14-1 
shKIF14-2 
cyclin B1 
GAPDH 
p-Cdc2 
(Thr 161) 
c
y
c
li
n
 B
1
 
/G
A
P
D
H
(%
) 
p
-C
d
c
2
  
/G
A
P
D
H
(%
) 
SAS Ho-1-N-1 
B Ho-1-N-1 SAS A 
shMock shMock 
shKIF14-1 shKIF14-1 
shKIF14-2 shKIF14-2 
C
e
ll
 c
o
u
n
ts
 
C
e
ll
 c
o
u
n
ts
 
C
e
ll
 c
o
u
n
ts
 
DNA content DNA content 
Figure 4 
1000 
500 
600 
0 
0 
400 
200 
200 400 600 0 800 
0 
500 
1000 
1500 
200 400 600 0 800 
0 
500 
1000 
1500 
200 400 600 0 800 
0 
500 
1000 
1500 
200 400 600 0 800 
0 
500 
1000 
1500 
200 400 600 0 800 
0 
500 
1000 
1500 
200 400 600 0 800 
0 
500 
1000 
1500 
14.9% 10.6% 
25.9% 23.1% 
26.0% 32.9% 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biochemistry and Biophysics Reports  
Volume 3 - (September  2015) Pages 26-31 
平成 27年 10月 12日 公表済 
